Observational studyClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-Associated Liver Disease.
Observational study in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND &
aimsPatients with alcohol-associated liver disease (ALD) frequently have cardiometabolic risk factors (CMRFs); however, their association with clinical outcomes remains unclear. We assessed the impact of CMRFs on hepatic recompensation and survival for patients referred for early liver transplant (LT) for ALD.
methodsThis multicenter, retrospective cohort study assessed patients with ALD and less than 6 months of sobriety from alcohol who were evaluated for early LT. Data on CMRFs, including body mass index (BMI), history of diabetes (T2DM), hypertension (HTN), and hyperlipidemia (HLD), were collected. Primary outcomes were hepatic recompensation and survival without LT.
resultsSix hundred seventeen patients with a median Model for End-stage Liver Disease (MELD) 3.0 at referral of 27 (interquartile range [IQR], 19-35) were included. A total of 307 patients (50%) were declined for LT or ultimately removed from the waitlist. Having any CMRFs was associated with decreased hepatic recompensation at 6 months (adjusted hazard ratio [aHR], 0.85; 95% confidence interval [CI], 0.74-0.98; P = .03), 12 months (aHR, 0.82; 95% CI, 0.70-0.97; P = .02), and 24 months (aHR, 0.71; 95% CI, 0.57-0.88; P < .01) post LT referral, with T2DM and elevated BMI playing the biggest role. In an adjusted competing risk analysis, higher BMI per kg/m
conclusionsCMRFs-particularly T2DM and elevated BMI-were associated with lower recompensation and survival in patients declined for early LT for ALD, even when controlling for disease severity. These findings highlight the importance of considering CMRFs when weighing the potential for recompensation and need for transplantation in patients considered for early LT for ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.